États-Unis · Agences & temps réel · PR Newswire

Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026

Publié par PR Newswire · États-Unis il y a 1 h

Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity observed…

Lire l'article complet sur PR Newswire Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.prnewswire.com)

Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026

À lire aussi

Brazil’s Lula opens state toolbox to woo voters in runoff against Bolsonaro. Here’s what is on offer

Infinity Hires Meta Superintelligence Labs Chip Veteran and the CUDA Educator Who's Taught Two Million Engineers

Advancing Government Intelligence: Insights From the Data and Intelligence Training Forum

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows

Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026

Partager

À lire aussi

Brazil’s Lula opens state toolbox to woo voters in runoff against Bolsonaro. Here’s what is on offer

Infinity Hires Meta Superintelligence Labs Chip Veteran and the CUDA Educator Who's Taught Two Million Engineers

Advancing Government Intelligence: Insights From the Data and Intelligence Training Forum

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows